Here are selected research papers on the study of misfolded proteins (or prion particles) and how they affect brain diseases.


Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis


Modeling Parkinson’s Disease with the Alpha Synuclein Protein


Lewy body dementia: The caregiver experience of clinical care


a-Syn in the pathophysiology of AD


Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease


α-Synuclein in cerebrospinal fluid of Alzheimer’s Disease and Mild Cognitive Impairment.


Treatment of Dementia with Lewy Bodies


Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium


The costs of dementia subtypes to California Medicare fee-for-service, 2015


Discriminating α-Synuclein strains in Parkinson’s disease and multiple system atrophy (Shahnawaz et al 2020)


Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies

Do good by doing well, do well by doing good.”

– Russ Lebovitz, CEO & CoFounder


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.